$15.97+0.22 (+1.40%)
First Tracks Biotherapeutics, Inc.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist th...
Grupo Traxión is in focus after a major global bank cut its MX$ price target by MX$6, pointing to a more restrained view on the stock. The shift lines up with recent research that adopts a more cautious tone on parts of the story, even as some analysts keep a constructive stance. As you read on, you will see how this evolving narrative could shape the way you track and interpret future updates around the stock. Stay updated as the Fair Value for Grupo Traxión. de shifts by adding it to your...
AnaptysBio, Inc. (NASDAQ:ANAB) is one of the best performing healthcare stocks so far in 2026. Piper Sandler cut the price target on AnaptysBio, Inc. (NASDAQ:ANAB) to $93 from $95 on May 4, reaffirming an Overweight rating on the shares. The firm stated that the company announced in April 2026 the completion of the First Tracks […]
AnaptysBio's (ANAB) board has approved the planned spin-off of First Tracks Biotherapeutics and a re